Title: Role of Her-2 Neu as Prognostic Indicator in Surface Epithelial Tumors of Ovary
Authors: B.Krishnaswamy, T.Arivazhagan, K.R.Gopalakrishnan, U.Manohar, M.Dhanalakshmi
DOI: https://dx.doi.org/10.18535/jmscr/v6i10.197
Abstract
Introduction: Ovarian carcinomas are the chief cause of death among women. Presently so many biomarkers are accessible for the early detection of the ovarian carcinomas like P53, EGFR, Ki67, CK, HER 2/ Neu. In this study we analyze the prognostic significance of HER 2/Neu in various surface epithelial ovarian tumors.
Aims of the study: To know the prognostic significance of HER-2/Neu in surface epithelial ovarian tumor.
Materials and Methods: The Present study was conducted in Rajah Muthiah Medical College and Hospital, Chidambaram.10 cases were randomly selected. Ovarian tumour that occurred from May 2013 to April 2018. Immunohistochemical analysis was done with HER2/Neu receptor marker for the 10 cases.
Conclusion: HER 2 /Neu expression is significantly not associated with tumor grade, tumor type and patient’s age.
Keywords: Surface epithelial ovarian tumours, HER 2/Neu, Cystic ovarian tumours.
References
- Luo H, Xu X, Ye M, Sheng B, Zhu X (2018) the prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies. PLoS ONE 13(1): e0191972
- Tavassoli FA, Devilee P. Pathology and genetics of tumors of breast and female genital organs. World Health Organisation classification of tumors .IARC Press, Lyon, 2003; 123-24.
- Hanna L, Adams M. Prevention of ovarian cancer. Best Practical Residents Clinical Obstetrics Gynaecology 2006; 20: 339-62.
- Nida Iqbal and Naveed Iqbal, “Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications,” Molecular Biology International, vol. 2014, Article ID 852748, 9 pages, 2014.
- Goel, et al.: Study of HER2/Neu Oncogene in Benign and Malignant Ovarian Tumors, International Journal of Scientific Study |July 2014 | Vol 2 | Issue 4.
- C. Marinas et al. EGFR, HER2/Neu and Ki 67 immunoexpression in serousovarian tumours. Rom J Morphol Embryol 2012; 53(3):563-567.
- Hadeel A. Kerbel, Rehab H. Abdul Saheb and Dhafer S. Alabbasi, Expression of p53 and HER2/Neu in serous ovarian carcinoma with different grades of differentiation (immunohistochemical study) .
- Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE. Overexpressionof HER2 in ovarian carcinomas. Cancer Res. 2001;61:2420-2423
- Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz AB Jr. Immunocyto-chemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 1990;125:107-13.